



Thomas Kirchner

Contact

Thomas Kirchner

Publications (16)

Jurmeister P, Büttner R, Merkelbach-Bruse S, Kreipe H, Jonigk D, Jochum W, Rodriguez R, Dietel M, Horst D, Hummel M, Kirchner T, Neumann J, Vollbrecht C, Jöhrens K, Aust D, Behnke A, Stenzinger A, Penzel R, Endris V, Schirmacher P, Fisseler-Eckhoff A, von Laffert M. Status quo of ALK testing in lung cancer: results of an EQA scheme based on in-situ hybridization, immunohistochemistry, and RNA/DNA sequencing. *Virchows Arch* 2021; 479:247-255.

Marchetto A, Dallmayer M, Romero-Pérez L, Hölting T, Amatruda J, Cossarizza A, Henssen A, Kirchner T, Moretti M, Cidre-Aranaz F, Sannino G, Musa J, Baldauf M, Gerke J, Ohmura S, Orth M, Knott M, Colombo M, Arrigoni C, Bardinet V, Saucier D, Wehweck F, Li J, Stein S, Grünewald T. Oncogenic hijacking of a developmental transcription factor evokes vulnerability toward oxidative stress in Ewing sarcoma. *Nat Commun* 2020; 11:2423.

Orth M, Li J, Marchetto A, Henssen A, Özen Ö, Sugita S, Hasegawa T, Kanaseki T, Bertram S, Dirksen U, Hartmann W, Kirchner T, Ohmura S, Gerke J, Cidre-Aranaz F, Hölting T, Dallmayer M, Wehweck F, Paul T, Musa J, Baldauf M, Surdez D, Delattre O, Knott M, Romero-Pérez L, Kasan M, Grünewald T. High Specificity of BCL11B and GLG1 for EWSR1-FLI1 and EWSR1-ERG Positive Ewing Sarcoma. *Cancers (Basel)* 2020; 12

Musa J, Stein S, Sannino G, Li J, Romero-Pérez L, Westermann F, Hartmann W, Dirksen U, Gymrek M, Anderson N, Shlien A, Rotblat B, Kirchner T, Delattre O, Baldauf M, Dallmayer M, Marchetto A, Cidre-Aranaz F, Aynaud M, Orth M, Knott M, Mirabeau O, Mazor G, Varon M, Hölting T, Grossetête S, Gartlgruber M, Surdez D, Gerke J, Ohmura S, Grünewald T. Cooperation of cancer drivers with regulatory germline variants shapes clinical outcomes. *Nat Commun* 2019; 10:4128.

Dallmayer M, Sannino G, Bach H, Kirchner T, Marchetto A, Orth M, Gerke J, Romero-Pérez L, Wehweck F, Cidre-Aranaz F, Stein S, Knott M, Musa J, Hölting T, Baldauf M, Alba Rubio R, Ohmura S, Li J, Grünewald T. Targeting the CALCB/RAMP1 axis inhibits growth of Ewing sarcoma. *Cell Death Dis* 2019; 10:116.

Orth M, Sannino G, Knott M, Wehweck F, Ohmura S, Li J, Hakozaiki M, Kirchner T, Dandekar T, Butt E, Marchetto A, Baldauf M, Dallmayer M, Gerke J, Knösel T, Altendorf-Hofmann A, Musa J, Alba-Rubio R, Stein S, Hölting T, Cidre-Aranaz F, Romero-Pérez L, Grünewald T. Functional genomics identifies AMPD2 as a new prognostic marker for undifferentiated pleomorphic sarcoma. *Int J Cancer* 2018; 144:859-867.

Baldauf M, Hasegawa T, Sugimura H, Baumhoer D, Knott M, Sannino G, Marchetto A, Li J, Busch D, Feuchtinger T, Ohmura S, Orth M, Thiel U, Kirchner T, Sugita S, Özen Ö, Gerke J, Kirschner A, Blaeschke F, Effenberger M, Schober K, Rubio R, Kanaseki T, Kiran M, Dallmayer M, Musa J, Akpolat N, Akatli A, Rosman F, Grünewald T. Systematic identification of cancer-specific MHC-binding peptides with RAVEN. *Oncoimmunology* 2018; 7:e1481558.

Baldauf M, Gerke J, Orth M, Dallmayer M, Baumhoer D, de Alava E, Hartmann W, Kirchner T, Grünewald T. Are EWSR1-NFATc2-positive sarcomas really Ewing sarcomas?. *Mod Pathol* 2018; 31:997-999.

Baldauf M, Akatli A, Özen Ö, Dirksen U, Hartmann W, de Alava E, Baumhoer D, Sannino G, Kirchner T, Akpolat N, Li J, Ohmura S, Orth M, Dallmayer M, Marchetto A, Gerke J, Rubio R, Kiran M, Musa J, Knott M, Grünewald T. Robust diagnosis of Ewing sarcoma by immunohistochemical detection of super-enhancer-driven EWSR1-ETS targets. *Oncotarget* 2017; 9:1587-1601.

Endris V, Weichert W, Dietel M, Höfler G, Jochum W, Büttner R, Kirchner T, Kreipe H, Lehmann U, Jung A, Sabine-Merkelbach-Bruse, Hummel M, Darb-Esfahani S, Lenze D, Möbs M, Penzel R, Pfarr N, Stenzinger A, Schirmacher P. NGS-based BRCA1/2 mutation testing of high-grade serous ovarian cancer tissue: results and conclusions of the first international round robin trial. *Virchows Arch* 2016; 468:697-705.

V Laffert M, Wölfel C, Petersen I, Rodriguez R, Jochum W, Bartsch H, Fisseler-Eckhoff A, Berg E, Lenze D, Dietel M, Kirchner T, Jung A, Kerler R, Warth A, Penzel R, Schirmacher P, Jonigk D, Kreipe H, Schildhaus H, Merkelbach-Bruse S, Büttner R, Reu S, Hummel M. Anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer (NSCLC): results of a multi-centre ALK-testing. *Lung Cancer* 2013; 81:200-6.

Wassermann S, Kirchner T, Brabletz T, Merkel S, Reu S, Kriegl L, Haynl A, Hlubek F, Horst D, Palmqvist R, Hiendlmeyer E, Scheel S, Jung A. p16INK4a is a beta-catenin target gene and indicates low survival in human colorectal tumors. *Gastroenterology* 2009; 136:196-205.e2.

Beiter K, Hiendlmeyer E, Brabletz T, Hlubek F, Haynl A, Knoll C, Kirchner T, Jung A. beta-Catenin regulates the expression of tenascin-C in human colorectal tumors. *Oncogene* 2005; 24:8200-4.

Brabletz T, Hlubek F, Spaderna S, Schmalhofer O, Hiendlmeyer E, Jung A, Kirchner T. Invasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem cells and beta-catenin. *Cells Tissues Organs (Print)* 2005; 179:56-65.

Hiendlmeyer E, Kirchner T, Brabletz T, Reuning U, van Beest M, Knoll C, Koch C, Dimmler A, Haynl A, Hlubek F, Wassermann S, Regus S, Jung A. Beta-catenin up-regulates the expression of the urokinase plasminogen activator in human colorectal tumors. *Cancer Res* 2004; 64:1209-14.

Ruckert S, Kirchner T, Brabletz T, Rüschoff J, Koch C, Haynl A, Dietmaier W, Beyser K, Oswald U, Brueckl W, Hiendlmeyer E, Jung A. T-cell factor-4 frameshift mutations occur frequently in human microsatellite instability-high colorectal carcinomas but do not contribute to carcinogenesis. *Cancer Res* 2002; 62:3009-13.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch